NCT03890952View on ClinicalTrials.gov

Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

February 1, 2023

Study Completion Date

August 1, 2024

Conditions
Recurrent Adult Brain Tumor
Interventions
DRUG

Nivolumab

Treatment with the combination of Nivolumab and bevacizumab every 2 weeks

DRUG

Bevacizumab

Treatment with the combination of Nivolumab and bevacizumab every 2 weeks

Trial Locations (1)

Unknown

Rigshospitalet, Copenhagen

All Listed Sponsors
collaborator

Herlev Hospital

OTHER

collaborator

University of Copenhagen

OTHER

lead

Ulrik Lassen

OTHER

NCT03890952 - Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter